Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare

Cellecta  

Charles River Discovery

Elsevier 

 NanoString     

 SeraCare 

Silicon Biosystems   

 Streck 

 TriMetis


XIFIN

  View All Sponsors 


Cambridge Healthtech Institute’s Third Annual

Biomarkers for Cancer Immunotherapy

Next-Generation Biomarkers for Combination Therapies: Beyond PD-1 and PD-L1

February 23-24 | Hilton San Francisco Union Square | San Francisco, CA
Part of the 24th International Molecular Medicine Tri-Conference

 

As results from immunotherapy trials roll in, new biomarkers are being proposed, including inflammatory cell features, tumor mutational burden, gene expression profiles, and the presence of DNA repair defects. Still, additional biomarkers are needed to prioritize and tailor patient treatment so that combination therapies can be used for patients with poor response to traditional therapies. PD-1 and PD-L1 are establishing themselves accepted biomarkers for cancer immunotherapies, but research is moving beyond checkpoint inhibitors and into co-stimulatory agents and cellular therapies. Cambridge Healthtech Institute’s Third Annual Biomarkers for Cancer Immunotherapy symposium will provide a forward-looking perspective at the diagnostics side of immune-oncology. Speakers will address the development of predictive and prognostic IO biomarkers, utility of these biomarkers in clinical trials, and their potential as companion diagnostics. Overall, this event will provide solutions to bridge the gap between biomarkers and therapy selection and monitoring.

Who should attend: VPs, Directors, Managers, CEOs, CSOs, Professors and Scientists from Large Pharma, Biotechs and Academia working in fields such as Cancer Biomarkers, T Cell Engineering, Gene and Cell Therapy, Cellular Biology, Immunology, Immunotherapy, Combination Therapies, Oncology, and Pathology

Topics may include, but are not limited to:

  • The biology of immune cells
    • T cells
    • B cells
    • NK cells, etc.

  • PD-1, PD-L1 status update: what was successful and what has failed?
  • Biomarkers beyond checkpoint inhibition: where do we go from here?

  • Biomarker discovery for combination therapies
  • Ensuring safety in immunotherapies
  • Integrating IO into the precision medicine model
  • Biomarkers in hematological and solid tumors
  • Is there a financial case for using or not using biomarkers?

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is July 15, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.  Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Samantha Drinkwater
Senior Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5461
E: sdrinkwater@healthtech.com

Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com

Joseph Vacca (Companies L-Z)
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com